Ohyashiki K, Yoshida M A, Gibas L M, Ohyashiki J H, Katsunuma H, Ryan D H, Rowe J, Sandberg A A
Cancer Genet Cytogenet. 1986 Apr 15;21(4):287-95. doi: 10.1016/0165-4608(86)90207-4.
Cytogenetic studies were performed on two patients with myelodysplastic syndromes. One patient was a 68 year old Japanese male in whose bone marrow cells two translocations were established, i.e., t(4;11)(q13;q23) and t(11;17)(q11?;q11), as well as other karyotypic changes (-6,-18,15p+). The other patient was a 74 year old white male whose bone marrow cells showed six marker chromosomes, i.e., der(5),t(5;17)(q12;q11), der(6),t(6;5)(q27;q22), der(8),t(8;11;?)(q11;q11----q23;?), der(11),t(11;?)(q11;?), an isochromosome of the long arm of chromosome #8, and a small G-group sized marker chromosome of unknown origin. Though the translocation patterns in the abnormal cells in these two cases were different, the breakpoints of the marker chromosomes were almost the same, i.e., 11q11, 11q23, and 17q11. Also, changes of chromosome #6 were observed; the first case showed monosomy 6 and the second a 6q+ marker chromosome. In these two cases of myelodysplastic syndromes, common sites of chromosome breakage and reunion of 11q23 and 17q11 were close to recently established sites of human cellular oncogene homologs, c-ets (11q23) and c-erbA (17q21----24). These associations draw attention to a possible relationship between chromosome changes in myelodysplastic syndromes and oncogene (or other gene) activation and/or dysfunction.
对两名骨髓增生异常综合征患者进行了细胞遗传学研究。一名患者是一名68岁的日本男性,其骨髓细胞中发现了两种易位,即t(4;11)(q13;q23)和t(11;17)(q11?;q11),以及其他核型变化(-6、-18、15p+)。另一名患者是一名74岁的白人男性,其骨髓细胞显示出6条标记染色体,即der(5)、t(5;17)(q12;q11)、der(6)、t(6;5)(q27;q22)、der(8)、t(8;11;?)(q11;q11----q23;?)、der(11)、t(11;?)(q11;?)、8号染色体长臂的一条等臂染色体,以及一条来源不明的小G组大小的标记染色体。尽管这两例异常细胞中的易位模式不同,但标记染色体的断点几乎相同,即11q11、11q23和17q11。此外,还观察到了6号染色体的变化;第一例显示6号染色体单体,第二例显示一条6q+标记染色体。在这两例骨髓增生异常综合征中,11q23和17q11的染色体断裂和重连的常见位点接近最近确定的人类细胞癌基因同源物c-ets(11q23)和c-erbA(17q21----24)的位点。这些关联引起了人们对骨髓增生异常综合征染色体变化与癌基因(或其他基因)激活和/或功能障碍之间可能关系的关注。